Facing a life-threatening illness can be a terrifying experience, and when it comes to meningococcal meningitis, the fear is completely justified. This aggressive bacterial infection can strike rapidly, sometimes leading to death within hours, or causing long-term complications even for those who survive. So, why aren't meningococcal vaccines recommended for everyone, especially those over 23? Let's dive in.
Dr. Roach, in response to a concerned reader, clarifies the reasoning behind these recommendations. The core principle guiding vaccination recommendations is simple: the benefits must outweigh the risks. This also involves considering the cost-effectiveness of the intervention.
In the case of meningococcal vaccines, the vaccines themselves are incredibly safe and effective. But here's where it gets controversial... Because the disease is relatively rare, vaccinating everyone isn't considered cost-effective. The focus is on protecting those at higher risk. These include individuals with an increased likelihood of exposure or those with a higher risk of severe disease due to immune deficiencies.
The current recommendations target adolescents and young adults, particularly those living in close proximity, such as college dormitories, where the risk of exposure is higher. The MenACWY vaccine is ideally given between ages 11-12, followed by a booster dose before college entry. The MenB vaccine is recommended in two doses, six months apart, between ages 16-18. But this is not the end of the story...
Beyond these age groups, the vaccine is also recommended for individuals with HIV infections, those without a functioning spleen (due to surgery, sickle cell disease, or other causes), people with specific immune system problems (complement deficiency), and those taking drugs that inhibit the complement system. Additionally, lab workers exposed to meningococcus are advised to get vaccinated.
And this is the part most people miss... The cost-effectiveness of widespread meningococcal vaccination is low. It can cost around $10 million to prevent a single death, even among college students. The cost would be significantly higher for healthy adults not living in high-risk environments. This is largely due to the rarity of the disease, with an incidence of approximately 1 case per 400,000 people annually before the vaccine was recommended. Recent studies show the incidence is now about 1 case per 1 million people each year. The success of the vaccine has further reduced the disease's prevalence.
Dr. Roach's personal decision to vaccinate his child before college highlights the peace of mind that comes with this preventative measure. However, he himself has not been vaccinated, as his risk has been very low since the vaccine's approval.
Due to the low prevalence of the disease and the high cost of the vaccine, it's not recommended for healthy adults. However, public health officials may recommend the vaccine more broadly during an outbreak.
What do you think? Do you agree with the current recommendations, or do you believe that more widespread vaccination is necessary, regardless of the cost? Share your thoughts in the comments below!
